Ott Muriel, Nagamany Thanoosha, Zandi Souska, Pichi Francesco, Agarwal Aniruddha, Carreño Ester, Gupta Vishali, Grewal Dilraj S, Cunningham Emmett T, Munk Marion R
Department of Ophthalmology, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland.
Cleveland Clinic Lerner College of Medicine, Case Western Reserve University, Cleveland, OH, United States.
Front Med (Lausanne). 2023 Sep 22;10:1242225. doi: 10.3389/fmed.2023.1242225. eCollection 2023.
To report a case series of herpetic uveitis following COVID-19 vaccinations.
Demographic, clinical and treatment-related data of herpetic anterior uveitis cases was collected at five tertiary eye hospitals between January 2021 and June 2022. A retrospective database review at one of the centers comparing the number of cases of herpetic eye disease before and after the introduction of COVID-19 vaccination was performed as well.
Twenty-four patients (9 female, 15 male) with a mean age of 54 years (range 28-83 years) were diagnosed with herpetic uveitis, reporting an onset of symptoms 3-42 days after the first, second or third dose of COVID-19 vaccination. Median time between vaccination and onset of herpetic eye disease was 10 days (mean 12.7 ± 10.15 days) days. The administered vaccines were BNT162b2, mRNA-1273, BBIBP-CorV and Ad26.COV2.S. The cases included 11 HSV, 10 VZV and 1 CMV anterior uveitis, 2 were not further specified. There was an equal number of first episodes ( = 12, 50%) and recurrent episodes ( = 12, 50%). Response to established regimens was generally good. The retrospective database review revealed the exact same incidence of herpetic uveitis during the pandemic and ongoing vaccination compared to prior SARS-CoV-2.
This report includes 24 cases of herpetic anterior uveitis in a temporal relationship to various COVID-19 vaccines. This study supports the potential risk of herpetic eye disease following COVID-19 vaccines, but proof of a direct, causal relationship is missing.
报告一系列新冠病毒疫苗接种后发生的疱疹性葡萄膜炎病例。
收集了2021年1月至2022年6月期间五家三级眼科医院疱疹性前葡萄膜炎病例的人口统计学、临床和治疗相关数据。还对其中一个中心进行了回顾性数据库审查，比较了新冠病毒疫苗接种前后疱疹性眼病的病例数。
24例患者（9例女性，15例男性）被诊断为疱疹性葡萄膜炎，报告在接种第一剂、第二剂或第三剂新冠病毒疫苗后3至42天出现症状。接种疫苗与疱疹性眼病发作之间的中位时间为10天（平均12.7±10.15天）。所接种的疫苗为BNT162b2、mRNA-1273、BBIBP-CorV和Ad26.COV2.S。病例包括11例单纯疱疹病毒（HSV）、10例水痘带状疱疹病毒（VZV）和1例巨细胞病毒（CMV）前葡萄膜炎，2例未进一步明确。初发病例（n = 12，50%）和复发病例（n = 12，50%）数量相等。对既定治疗方案的反应总体良好。回顾性数据库审查显示，与之前的严重急性呼吸综合征冠状病毒2（SARS-CoV-2）相比，在疫情期间和持续接种疫苗期间疱疹性葡萄膜炎的发病率完全相同。
本报告包括24例与各种新冠病毒疫苗存在时间关联的疱疹性前葡萄膜炎病例。本研究支持了新冠病毒疫苗接种后发生疱疹性眼病的潜在风险，但缺乏直接因果关系的证据。
